REFERENCES
2. Boucly A, Gerges C, Savale L, et al. Pulmonary arterial hypertension. Presse Med. 2023;52:104168.
3. Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019;53:1801887.
4. Kovacs G, Bartolome S, Denton CP, et al. Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J. 2024;64:2401324.
6. Sun L, Tian H, Liu J, et al. The role of the pulmonary vascular microenvironment in chronic thromboembolic pulmonary hypertension. Pulm Circ. 2025;15:e70118.
7. Ruaro B, Baratella E, Caforio G, et al. Chronic thromboembolic pulmonary hypertension: an update. Diagnostics. 2022;12:235.
8. Mocumbi A, Humbert M, Saxena A, et al. Publisher Correction: pulmonary hypertension. Nat Rev Dis Primers. 2024;10:5.
9. Naeije R, Richter MJ, Rubin LJ. The physiological basis of pulmonary arterial hypertension. Eur Respir J. 2022;59:2102334.
10. Dai J, Chen H, Fang J, Wu S, Jia Z. Vascular remodeling: the multicellular mechanisms of pulmonary hypertension. Int J Mol Sci. 2025;26:4265.
11. Gallardo-vara E, Ntokou A, Dave JM, Jovin DG, Saddouk FZ, Greif DM. Vascular pathobiology of pulmonary hypertension. J Heart Lung Transplant. 2023;42:544-52.
12. Guignabert C, Aman J, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: current insights and future directions. Eur Respir J. 2024;64:2401095.
13. Christou H, Khalil RA. Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies. Am J Physiol Heart Circ Physiol. 2022;322:H702-24.
14. Shen Y, Goncharov DA, Pena A, et al. Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension. Sci Signal. 2022;15:eabn2743.
15. Thenappan T, Chan SY, Weir EK. Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2018;315:H1322-31.
16. Liu F, Haeger CM, Dieffenbach PB, et al. Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertension. JCI Insight. 2016;1:e86987.
17. Mamazhakypov A, Maripov A, Sarybaev AS, Schermuly RT, Sydykov A. Osteopontin in pulmonary hypertension. Biomedicines. 2023;11:1385.
18. Chastney MR, Kaivola J, Leppänen V, Ivaska J. The role and regulation of integrins in cell migration and invasion. Nat Rev Mol Cell Biol. 2024;26:147-67.
22. Lemay S, Montesinos MS, Grobs Y, et al. Exploring integrin α5β1 as a potential therapeutic target for pulmonary arterial hypertension: insights from comprehensive multicenter preclinical studies. Circulation. 2025;151:1162-83.
23. Umesh A, Paudel O, Cao Y, Myers AC, Sham JS. Alteration of pulmonary artery integrin levels in chronic hypoxia and monocrotaline-induced pulmonary hypertension. J Vasc Res. 2011;48:525-37.
24. Suezawa T, Kanagaki S, Moriguchi K, et al. Disease modeling of pulmonary fibrosis using human pluripotent stem cell-derived alveolar organoids. Stem Cell Rep. 2021;16:2973-87.
25. Bellani S, Molyneaux PL, Maher TM, Spagnolo P. Potential of αvβ6 and αvβ1 integrin inhibition for treatment of idiopathic pulmonary fibrosis. Expert Opin Ther Targets. 2024;28:575-85.
26. Gasparri AM, Pocaterra A, Colombo B, et al. Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth. J Exp Clin Cancer Res. 2025;44:88.
27. Bi Z, Zang G, Wang X, Tian L, Zhang W. Integrins and pulmonary fibrosis: pathogenic roles and therapeutic opportunities. Biomol Biomed. 2025;26:200-14.
28. Jandl K, Radic N, Zeder K, Kovacs G, Kwapiszewska G. Pulmonary vascular fibrosis in pulmonary hypertension - The role of the extracellular matrix as a therapeutic target. Pharmacol Ther. 2023;247:108438.
29. Yang Q, Chen P, He X, et al. Melk facilitates pulmonary artery smooth muscle cell proliferation and migration in pulmonary hypertension via modulation of YAP/TAZ signaling. Front Cell Dev Biol. 2025;13:1693346.
30. Zhao T, Huang Y, Zhu J, et al. Extracellular matrix signaling cues: biological functions, diseases, and therapeutic targets. MedComm. 2025;6:e70281.
31. Pang X, He X, Qiu Z, et al. Targeting integrin pathways: mechanisms and advances in therapy. Sig Transduct Target Ther. 2023;8:1.
32. Tamkun JW, Desimone DW, Fonda D, et al. Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell. 1986;46:271-82.
33. Hynes RO. The emergence of integrins: a personal and historical perspective. Matrix Biol. 2004;23:333-40.
34. Campbell ID, Humphries MJ. Integrin structure, activation, and interactions. Cold Spring Harb Perspect Biol. 2011;3:a004994.
35. Hemler ME, Jacobson JG, Brenner MB, Mann D, Strominger JL. VLA‐1: a T cell surface antigen which defines a novel late stage of human T cell activation. Eur J Immunol. 2005;15:502-8.
37. Hamaia SW, Pugh N, Raynal N, et al. Mapping of potent and specific binding motifs, GLOGEN and GVOGEA, for integrin α1β1 using collagen toolkits II and III. J Biol Chem. 2012;287:26019-28.
38. Zeltz C, Gullberg D. The integrin-collagen connection - a glue for tissue repair? J Cell Sci. 2016;129:653-64.
40. Ramovs V, Te Molder L, Sonnenberg A. The opposing roles of laminin-binding integrins in cancer. Matrix Biol. 2017;57-8:213-43.
42. Couvelard A, Bringuier A, Dauge M, et al. Expression of integrins during liver organogenesis in humans. Hepatology. 1998;27:839-47.
43. Lora JM, Rowader KE, Soares L, Giancotti F, Zaret KS. α3β1-integrin as a critical mediator of the hepatic differentiation response to the extracellular matrix. Hepatology. 1998;28:1095-104.
44. Kreidberg JA, Donovan MJ, Goldstein SL, et al. Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development. 1996;122:3537-47.
45. Kim YY, Lim CS, Song YH, Ahnn J, Park D, Song WK. Cellular localization of α3β1 integrin isoforms in association with myofibrillogenesis during cardiac myocyte development in culture. Cell Adhes Commun. 2009;7:85-97.
46. Guenther C. β2-integrins - regulatory and executive bridges in the signaling network controlling leukocyte trafficking and migration. Front Immunol. 2022;13:809590.
49. Hou J, Yan D, Liu Y, Huang P, Cui H. The roles of integrin α5β1 in human cancer. Onco Targets Ther. 2020;13:13329-44.
50. Renner G, Noulet F, Mercier M, et al. Expression/activation of α5β1 integrin is linked to the β-catenin signaling pathway to drive migration in glioma cells. Oncotarget. 2016;7:62194-207.
51. Lv X, Li Z, Guan J, et al. Porcine hemagglutinating encephalomyelitis virus activation of the integrin α5β1-FAK-cofilin pathway causes cytoskeletal rearrangement to promote its invasion of N2a cells. J Virol. 2019;93:e01736-18.
52. Oh S, Kim J, Kim Y, et al. The extracellular matrix protein Edil3 stimulates osteoblast differentiation through the integrin α5β1/ERK/Runx2 pathway. PLoS ONE. 2017;12:e0188749.
53. López-luppo M, Catita J, Ramos D, et al. Cellular senescence is associated with human retinal microaneurysm formation during aging. Invest Ophthalmol Vis Sci. 2017;58:2832.
54. Di Maggio N, Martella E, Frismantiene A, et al. Extracellular matrix and α5β1 integrin signaling control the maintenance of bone formation capacity by human adipose-derived stromal cells. Sci Rep. 2017;7:44398.
55. Delwel GO, De Melker AA, Hogervorst F, et al. Distinct and overlapping ligand specificities of the alpha 3A beta 1 and alpha 6A beta 1 integrins: recognition of laminin isoforms. Mol Biol Cell. 1994;5:203-15.
56. Hayashi YK, Chou F, Engvall E, et al. Mutations in the integrin α7 gene cause congenital myopathy. Nat Genet. 1998;19:94-7.
57. Mayer U, Saher G, Fässler R, et al. Absence of integrin α7 causes a novel form of muscular dystrophy. Nat Genet. 1997;17:318-23.
58. Flintoff‐dye NL, Welser J, Rooney J, et al. Role for the α7β1 integrin in vascular development and integrity. Dev Dyn. 2005;234:11-21.
60. Zargham R. Tensegrin in context: dual role of α8 integrin in the migration of different cell types. Cell Adh Migr. 2014;4:485-90.
61. Nishimichi N, Tsujino K, Kanno K, et al. Induced hepatic stellate cell integrin, α8β1, enhances cellular contractility and TGFβ activity in liver fibrosis. J Pathol. 2021;253:366-73.
62. Guo Q, Furuta K, Lucien F, et al. Integrin β1-enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine NASH. J Hepatol. 2019;71:1193-205.
63. Honda M, Kimura C, Uede T, Kon S. Neutralizing antibody against osteopontin attenuates non-alcoholic steatohepatitis in mice. J Cell Commun Signal. 2020;14:223-32.
64. Lundgren-Åkerlund E, Aszòdi A. Integrin α10β1: a collagen receptor critical in skeletal development. Adv Exp Med Biol. 2014;19:61-71.
65. Camper L, Holmvall K, Wängnerud C, Aszódi A, Lundgren-Åkerlund E. Distribution of the collagen-binding integrin α10β1 during mouse development. Cell Tissue Res. 2001;306:107-16.
66. Popova SN, Barczyk M, Tiger C, et al. α 11β1 integrin-dependent regulation of periodontal ligament function in the erupting mouse incisor. Mol Cell Biol. 2023;27:4306-16.
67. Han Z, Ma Y, Cao G, et al. Integrin αVβ1 regulates procollagen I production through a non-canonical transforming growth factor β signaling pathway in human hepatic stellate cells. Biochem J. 2021;478:1689-703.
68. Reed NI, Jo H, Chen C, et al. The αvβ1 integrin plays a critical in vivo role in tissue fibrosis. Sci Transl Med. 2015;7:288ra79.
69. Mitroulis I, Alexaki VI, Kourtzelis I, Ziogas A, Hajishengallis G, Chavakis T. Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther. 2015;147:123-35.
71. Schnitzler N, Haase G, Podbielski A, Lütticken R, Schweizer KG. A co-stimulatory signal through ICAM-β2 integrin-binding potentiates neutrophil phagocytosis. Nat Med. 1999;5:231-5.
72. Schenkel AR, Mamdouh Z, Muller WA. Locomotion of monocytes on endothelium is a critical step during extravasation. Nat Immunol. 2004;5:393-400.
73. Jawhara S, Pluskota E, Cao W, Plow EF, Soloviev DA. Distinct effects of integrins αXβ2 and αMβ2 on leukocyte subpopulations during inflammation and antimicrobial responses. Infect Immun. 2017;85:e00644-16.
74. Guenther C, Faisal I, Fusciello M, et al. β2-integrin adhesion regulates dendritic cell epigenetic and transcriptional landscapes to restrict dendritic cell maturation and tumor rejection. Cancer Immunol Res. 2021;9:1354-69.
75. Miyazaki Y, Vieira-De-Abreu A, Harris ES, et al. Integrin αDβ2 (CD11d/CD18) is expressed by human circulating and tissue myeloid leukocytes and mediates inflammatory signaling. PLoS ONE. 2014;9:e112770.
76. Yakubenko VP, Yadav SP, Ugarova TP. Integrin αDβ2, an adhesion receptor up-regulated on macrophage foam cells, exhibits multiligand-binding properties. Blood. 2006;107:1643-50.
77. Van Den Kerkhof DL, Van Der Meijden PE, Hackeng TM, Dijkgraaf I. Exogenous integrin αIIbβ3 inhibitors revisited: past, present and future applications. Int J Mol Sci. 2021;22:3366.
78. Kokubo T, Uchida H, Choi ET. Integrin αvβ3 as a target in the prevention of neointimal hyperplasia. J Vasc Surg. 2007;45:A33-8.
79. Bishop GG, Mcpherson JA, Sanders JM, et al. Selective αvβ3-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation. 2001;103:1906-11.
80. Guermonprez P, Valladeau J, Zitvogel L, Théry C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20:621-67.
81. Der Neut R, Krimpenfort P, Calafat J, Niessen CM, Sonnenberg A. Epithelial detachment due to absence of hemidesmosomes in integrin β4 null mice. Nat Genet. 1996;13:366-9.
82. Welser-alves JV, Boroujerdi A, Tigges U, Wrabetz L, Feltri ML, Milner R. Endothelial β4 integrin is predominantly expressed in arterioles, where it promotes vascular remodeling in the hypoxic brain. Arterioscle, Thromb Vasc Biol. 2013;33:943-53.
83. Porte J, Jenkins G, Tatler AL. Myofibroblast TGF-β activation measurement in vitro. Methods Mol Biol. 2021;2299:99-108.
84. Tatler AL, John AE, Jolly L, et al. Integrin αvβ5-mediated TGF-β activation by airway smooth muscle cells in asthma. J Immunol. 2011;187:6094-107.
85. Asano Y, Ihn H, Jinnin M, Mimura Y, Tamaki K. Involvement of αvβ5 integrin in the establishment of autocrine TGF-β signaling in dermal fibroblasts derived from localized scleroderma. J Investig Dermatol. 2006;126:1761-9.
86. Kumawat AK, Yu C, Mann EA, Schridde A, Finnemann SC, Mowat AM. Expression and characterization of αvβ5 integrin on intestinal macrophages. Eur J Immunol. 2018;48:1181-7.
87. Schiesser JV, Loudovaris T, Thomas HE, Elefanty AG, Stanley EG. Integrin αvβ5 heterodimer is a specific marker of human pancreatic beta cells. Sci Rep. 2021;11:8315.
88. Koivisto L, Bi J, Häkkinen L, Larjava H. Integrin αvβ6: structure, function and role in health and disease. Int J Biochem Cell Biol. 2018;99:186-96.
89. Madala SK, Korfhagen TR, Schmidt S, et al. Inhibition of the αvβ6 integrin leads to limited alteration of TGF-α-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014;306:L726-35.
90. Ansar M, Jan A, Santos-cortez RLP, et al. Expansion of the spectrum of ITGB6-related disorders to adolescent alopecia, dentogingival abnormalities and intellectual disability. Eur J Hum Genet. 2015;24:1223-7.
91. White JB, Hu LY, Boucher DL, Sutcliffe JL. ImmunoPET imaging of αvβ6 expression using an engineered anti-αvβ6 Cys-diabody site-specifically radiolabeled with Cu-64: considerations for optimal imaging with antibody fragments. Mol Imaging Biol. 2017;20:103-13.
92. Li H, Huang S, Shi F, Gu Z, Zhang S, Wei J. α4β7 integrin inhibitors: a patent review. Expert Opin Ther Pat. 2018;28:903-17.
93. Arthos J, Cicala C, Nawaz F, et al. The role of integrin α4β7 in HIV pathogenesis and treatment. Curr HIV/AIDS Rep. 2018;15:127-35.
94. Fukui T, Fukaya T, Uto T, et al. Pivotal role of CD103 in the development of psoriasiform dermatitis. Sci Rep. 2020;10:8371.
95. Cepek KL, Shaw SK, Parker CM, et al. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the αEβ7 integrin. Nature. 1994;372:190-3.
96. Zundler S, Becker E, Spocinska M, et al. Hobit- and Blimp-1-driven CD4+ tissue-resident memory T cells control chronic intestinal inflammation. Nat Immunol. 2019;20:288-300.
97. Zhou M, Niu J, Wang J, et al. Integrin αvβ8 serves as a novel marker of poor prognosis in colon carcinoma and regulates cell invasiveness through the activation of TGF-β1. J Cancer. 2020;11:3803-15.
98. Mccarty JH. αvβ8 integrin adhesion and signaling pathways in development, physiology and disease. J Cell Sci. 2020;133:jcs239434.
100. Sasaki T, Timpl R. Domain IVa of laminin α5 chain is cell‐adhesive and binds β1 and αVβ3 integrins through Arg‐Gly‐Asp. FEBS Lett. 2001;509:181-5.
101. Munksgaard Thorén M, Chmielarska Masoumi K, Krona C, et al. Integrin α10, a novel therapeutic target in glioblastoma, regulates cell migration, proliferation, and survival. Cancers. 2019;11:587.
102. Ludwig BS, Kessler H, Kossatz S, Reuning U. RGD-binding integrins revisited: how recently discovered functions and novel synthetic ligands (Re-)shape an ever-evolving field. Cancers. 2021;13:1711.
103. Xiao T, Takagi J, Coller BS, Wang J, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature. 2004;432:59-67.
104. Tselepis VH, Green LJ, Humphries MJ. An RGD to LDV motif conversion within the disintegrin kistrin generates an integrin antagonist that retains potency but exhibits altered receptor specificity. J Biol Chem. 1997;272:21341-8.
105. Lafoya B, Munroe J, Miyamoto A, et al. Beyond the matrix: the many non-ECM ligands for integrins. Int J Mol Sci. 2018;19:449.
106. Hussein HAM, Walker LR, Abdel-Raouf UM, Desouky SA, Montasser AKM, Akula SM. Beyond RGD: virus interactions with integrins. Arch Virol. 2015;160:2669-81.
107. Davis PJ, Mousa SA, Cody V, Tang H, Lin H. Small molecule hormone or hormone-like ligands of integrin αVβ3: implications for cancer cell behavior. Horm Canc. 2013;4:335-42.
108. Kechagia JZ, Ivaska J, Roca-Cusachs P. Integrins as biomechanical sensors of the microenvironment. Nat Rev Mol Cell Biol. 2019;20:457-73.
109. Moreno-layseca P, Icha J, Hamidi H, Ivaska J. Integrin trafficking in cells and tissues. Nat Cell Biol. 2019;21:122-32.
111. Boppart MD, Mahmassani ZS. Integrin signaling: linking mechanical stimulation to skeletal muscle hypertrophy. Am J Physiol Cell Physiol,. 2019;317:C629-41.
112. Lee J, Bankston LA, Robert C Liddington MAA. Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure. 1995;3:1333-40.
113. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol. 2010;11:288-300.
114. Rognoni E, Ruppert R, Fässler R. The kindlin family: functions, signaling properties and implications for human disease. J Cell Sci. 2016;129:17-27.
115. Böttcher RT, Veelders M, Rombaut P, et al. Kindlin-2 recruits paxillin and Arp2/3 to promote membrane protrusions during initial cell spreading. J Cell Biol. 2017;216:3785-98.
116. Zhao X, Guan J. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Delivery Rev. 2011;63:610-5.
117. Murphy JM, Jeong K, Lim SS. FAK family kinases in vascular diseases. Int J Mol Sci. 2020;21:3630.
118. Calderwood DA, Fujioka Y, De Pereda JM, et al. Integrin β cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proc Natl Acad Sci USA. 2003;100:2272-7.
119. Kanter RK. Pediatric Emergency intravenous access: evaluation of a protocol. Am J Dis Child. 1986;140:132.
120. Meisaprow P, Aksorn N, Vinayanuwattikun C, Chanvorachote P, Sukprasansap M. Caffeine induces G0/G1 cell cycle arrest and inhibits migration through integrin αv, β3, and FAK/Akt/c-Myc signaling pathway. Molecules. 2021;26:7659.
121. Yuan R, Li Y, Yang B, et al. LOXL1 exerts oncogenesis and stimulates angiogenesis through the LOXL1-FBLN5/αvβ3 integrin/FAK-MAPK axis in ICC. Mol Ther Nucl Acids. 2021;23:797-810.
122. Sun W, Chan SY. Pulmonary arterial stiffness: an early and pervasive driver of pulmonary arterial hypertension. Front Med. 2018;5:204.
123. Chelladurai P, Seeger W, Pullamsetti SS. Matrix metalloproteinases and their inhibitors in pulmonary hypertension. Eur Respir J. 2012;40:766-82.
124. Hindmarch CCT, Tian L, Xiong PY, et al. An integrated proteomic and transcriptomic signature of the failing right ventricle in monocrotaline induced pulmonary arterial hypertension in male rats. Front Physiol. 2022;13:966454.
125. Meng L, Liu X, Teng X, et al. Osteopontin plays important roles in pulmonary arterial hypertension induced by systemic‐to‐pulmonary shunt. FASEB J. 2019;33:7236-51.
126. Blanchard N, Link PA, Farkas D, et al. Dichotomous role of integrin‐β5 in lung endothelial cells. Pulm Circ. 2022;12:e12156.
127. Sun L, Li H, Li Y, et al. Proteomic insights into platelet dysregulation and pathogenic mechanisms of chronic thromboembolic pulmonary hypertension. J Transl Med. 2025;23:1074.
128. Befani C, Liakos P. Hypoxia upregulates integrin gene expression in microvascular endothelial cells and promotes their migration and capillary‐like tube formation. Cell Biol Int. 2017;41:769-78.
129. Webb DJ, Donais K, Whitmore LA, et al. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol. 2004;6:154-61.
130. Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol. 1999;71:435-78.
131. Aikawa R, Nagai T, Kudoh S, et al. Integrins play a critical role in mechanical stress-induced p38 MAPK activation. Hypertension. 2002;39:233-8.
132. Wang R, Xu J, Wu J, Gao S, Wang Z. Angiotensin‑converting enzyme 2 alleviates pulmonary artery hypertension through inhibition of focal adhesion kinase expression. Exp Ther Med. 2021;22:1165.
133. Mehta D, Tiruppathi C, Sandoval R, Minshall RD, Holinstat M, Malik AB. Modulatory role of focal adhesion kinase in regulating human pulmonary arterial endothelial barrier function. J Physiol. 2002;539:779-89.
134. Paulin R, Meloche J, Courboulin A, et al. Targeting cell motility in pulmonary arterial hypertension. Eur Respir J. 2014;43:531-44.
135. Chen H, Liu P, Pan X, et al. Downregulation of collagen IV deposition and ITGB1-FAK signaling pathway to inhibit adipogenesis: a novel mechanism of swertiamarin in treating type 2 diabetes mellitus. Int J Biol Macromol. 2025;299:140048.
136. Niit M, Hoskin V, Carefoot E, et al. Cell-cell and cell-matrix adhesion in survival and metastasis: Stat3 versus Akt. Biomol Concepts. 2015;6:383-99.
137. Liu C, Chen K, Wang H, et al. Gastrin attenuates renal ischemia/reperfusion injury by a PI3K/Akt/Bad-mediated anti-apoptosis signaling. Front Pharmacol. 2020;11:540479.
139. Sun T, Zhang J, Deng B, et al. FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of Bim. Acta Biochim Biophys Sin. 2020;52:1348-59.
141. Abeyrathna P, Kovacs L, Han W, Su Y. Calpain-2 activates Akt via TGF-β1-mTORC2 pathway in pulmonary artery smooth muscle cells. Am J Physiol Cell Physiol. 2016;311:C24-34.
142. Fan Z, Li C, Qin C, et al. Role of the PI3K/AKT pathway in modulating cytoskeleton rearrangements and phenotype switching in rat pulmonary arterial vascular smooth muscle cells. DNA Cell Biol. 2014;33:12-9.
143. Gu C, Yang Z, Su S, et al. 4-Terpineol attenuates pulmonary vascular remodeling via suppressing PI3K/Akt signaling pathway in hypoxia-induced pulmonary hypertension rats. Toxicol Appl Pharmacol. 2023;473:116596.
144. Vandamme D, Herrero A, Al-Mulla F, Kolch W. Regulation of the MAPK pathway by raf kinase inhibitory protein. Crit Rev Oncog. 2014;19:405-15.
145. Liu Y, Tang BL, Lu ML, Wang HX. Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1/2 pathway. J Cell Mol Med. 2023;27:622-33.
146. Church AC, Martin DH, Wadsworth R, et al. The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2015;309:L333-47.
147. Das M, Zawada WM, West J, Stenmark KR. JNK2 regulates vascular remodeling in pulmonary hypertension. Pulm Circ. 2018;8:1-13.
148. Ding Q, Stewart J, Olman MA, Klobe MR, Gladson CL. The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged. J Biol Chem. 2003;278:39882-91.
149. Ishigaki T, Imanaka‐yoshida K, Shimojo N, Matsushima S, Taki W, Yoshida T. Tenascin‐C enhances crosstalk signaling of integrin αvβ3/PDGFR‐β complex by SRC recruitment promoting PDGF‐induced proliferation and migration in smooth muscle cells. J Cell Physiol. 2011;226:2617-24.
150. Jia D, Zhu Q, Liu H, et al. Osteoprotegerin disruption attenuates HySu-induced pulmonary hypertension through integrin αvβ3/FAK/AKT pathway suppression. Circ Cardiovasc Genet. 2017;10:e001591.
151. Kökény G, Calvier L, Hansmann G. PPARγ and TGFβ—Major regulators of metabolism, inflammation, and fibrosis in the lungs and kidneys. Int J Mol Sci. 2021;22:10431.
152. Gorelova A, Berman M, Al Ghouleh I. Endothelial-to-mesenchymal transition in pulmonary arterial hypertension. Antioxid Redox Signal. 2021;34:891-914.
153. Bai P, Lyu L, Yu T, et al. Macrophage-derived legumain promotes pulmonary hypertension by activating the MMP (matrix metalloproteinase)-2/TGF (transforming growth factor)-β1 signaling. Arterioscler Thromb Vasc Biol. 2019;39:e130-45.
154. Rifkin D, Sachan N, Singh K, Sauber E, Tellides G, Ramirez F. The role of LTBPs in TGF beta signaling. Dev Dyn. 2021;251:75-84.
155. Munger JS, Huang X, Kawakatsu H, et al. A mechanism for regulating pulmonary inflammation and fibrosis: the integrin αvβ6 binds and activates latent TGF β1. Cell. 1999;96:319-28.
156. Margadant C, Sonnenberg A. Integrin-TGF‐β crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 2010;11:97-105.
157. Andreucci E, Bugatti K, Peppicelli S, et al. Nintedanib-αVβ6 integrin ligand conjugates reduce TGFβ-induced EMT in human non-small cell lung cancer. Int J Mol Sci. 2023;24:1475.
158. Decaris ML, Schaub JR, Chen C, et al. Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF. Respir Res. 2021;22:265.
159. Gao C, Li J, Feng F, et al. EDIL3 regulates pulmonary artery smooth muscle cell proliferation and migration via integrin αVβ3/ERK1/2 axis in pulmonary hypertension. Eur J Pharmacol. 2025;1003:177901.
160. Lafyatis R. Transforming growth factor β—at the centre of systemic sclerosis. Nat Rev Rheumatol. 2014;10:706-19.
161. Mitra A, Agarwal S, Chakraborty A, et al. Loss of ROR2 tyrosine kinase receptor is associated with endothelial dysfunction in PAH via inappropriate integrin β1 activation. Hypertension. 2026;83.
162. Qi R, Zhang Y, Yan F. Exosomes enriched by miR-429-3p derived from ITGB1 modified Telocytes alleviates hypoxia-induced pulmonary arterial hypertension through regulating Rac1 expression. Cell Biol Toxicol. 2024;40:32.
163. Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388:1478-90.
164. Ricart AD, Tolcher AW, Liu G, et al. Volociximab, a chimeric monoclonal antibody that specifically binds α5β1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res. 2008;14:7924-9.
165. Cianfrocca ME, Kimmel KA, Gallo J, et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. Br J Cancer. 2006;94:1621-6.
166. Yurdagul A, Green J, Albert P, Mcinnis MC, Mazar AP, Orr AW. α5β1 integrin signaling mediates oxidized low-density lipoprotein-induced inflammation and early atherosclerosis. Arterioscler Thromb Vasc Biol. 2014;34:1362-73.
167. Vansteenkiste J, Barlesi F, Waller C, et al. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). Ann Oncol. 2015;26:1734-40.
168. Macdonald TJ, Vezina G, Stewart CF, et al. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2013;15:1438-44.
169. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26:5610-7.
170. Vermorken J, Peyrade F, Krauss J, et al. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). Ann Oncol. 2014;25:682-8.
171. Zhou X, Zhang J, Haimbach R, et al. An integrin antagonist (MK‐0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model. Pharmaco Res Perspec. 2017;5:e00354.
172. Zhang J, Wang T, Saigal A, et al. Discovery of a new class of integrin antibodies for fibrosis. Sci Rep. 2021;11:2118.
173. John AE, Graves RH, Pun KT, et al. Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis. Nat Commun. 2020;11:4659.
174. Raghu G, Mouded M, Chambers DC, et al. A phase IIb randomized clinical study of an anti-αvβ6 monoclonal antibody in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2022;206:1128-39.
175. Mooney JJ, Jacobs S, Lefebvre ÉA, et al. Bexotegrast shows dose-dependent integrin αvβ6 receptor occupancy in lungs of participants with idiopathic pulmonary fibrosis: a phase 2, open-label clinical trial. Ann Am Thorac Soc. 2025;22:350-8.
176. Mu Y, Liu J, Wu Q, et al. A dual αvβ1/αvβ6 integrin inhibitor Bexotegrast (PLN-74809) ameliorates organ injury and fibrogenesis in fibrotic kidney disease. Eur J Pharmacol. 2024;983:176983.
177. Slack RJ, Macdonald SJF, Roper JA, Jenkins RG, Hatley RJD. Emerging therapeutic opportunities for integrin inhibitors. Nat Rev Drug Discov. 2021;21:60-78.
178. Li Z, Zhou Y, Ding Y, Guo Q, Zhao L. Roles of integrin in tumor development and the target inhibitors. Chin J Nat Med. 2019;17:241-51.
179. Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1100-8.
180. Agrawal V, Hemnes AR. Integrin targeting therapies in pulmonary arterial hypertension: a roadmap for traversing the translational valley of death? Circulation. 2025;151:1184-6.
181. Zhang S, Zhang Q, Lu Y, et al. Roles of integrin in cardiovascular diseases: from basic research to clinical implications. Int J Mol Sci. 2024;25:4096.
182. Simone E, Ding B, Muzykantov V. Targeted delivery of therapeutics to endothelium. Cell Tissue Res. 2008;335:283-300.
183. Zhou X, Liu H, Zhao H, Wang T. RGD-modified nanoliposomes containing quercetin for lung cancer targeted treatment. Onco Targets Ther. 2018;11:5397-405.
184. Castro Brás LE, Frangogiannis NG. Extracellular matrix-derived peptides in tissue remodeling and fibrosis. Matrix Biol. 2020;91-92:176-87.
185. Nikolov A, Popovski N. Extracellular matrix in heart disease: focus on circulating collagen type I and III derived peptides as biomarkers of myocardial fibrosis and their potential in the prognosis of heart failure: a concise review. Metabolites. 2022;12:297.
